Investment
Features
FeesSafety
Academy
More
Pluang+

US Congress allows up to 100% tariffs on Russian energy imports, targeting China and India.

Market News
18 Sep 2026
Seeking Alpha
View Source
Neutral
US Congress allows up to 100% tariffs on Russian energy imports, targeting China and India.

The US House passed the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, granting the executive branch authority to impose tariffs up to 100% on countries importing most Russian energy, focusing on China and India. The bill aims to pressure these nations to change their trade behavior and strengthen US leverage in global negotiations. India faces high costs to switch energy sources due to refinery specialization, while China has more flexibility but remains vulnerable to tariff threats. This move could accelerate the development of alternative financial systems outside US influence, though such changes will take time.

The US House's Lindsey O. Graham Sanctioning Russia and Iran Act of 2026 is the story's subject, offered here with Pluang platform market data for context. For readers following US stocks, here is Pluang's market snapshot as of Sep 18, 2026 19:01 WIB: out of 150 priced US stocks, 59 rose and 85 fell today. Notable movers include NIO at USD 3.69 with a 1-day change of +2.07%, GOOG at USD 350.69 with +2.04%, and HOOD at USD 111.97 with +1.97%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

In August, India's gold market showed resilience with steady jewelry buying and physical investment demand despite volatile gold prices. Domestic gold prices rose 12% in August but pulled back in September amid changing Fed policy expectations. Gold ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App